Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Randomized trial testing semaglutide versus placebo, both alongside lifestyle intervention, over 68 weeks.
GLP-1 and metabolic research
Read the weight, glucose, maintenance and safety findings behind GLP-1 and related metabolic therapies.
Start with the outcome
Weight change, HbA1c, cardiovascular events and maintaining a previous loss are different research questions. Start with the endpoint you care about, then check whether the study population and follow-up match it.
Compare the comparison
A randomized head-to-head trial, an indirect comparison and two unrelated trials support different conclusions. The size of a percentage on its own cannot rank treatments. Look for the comparator, confidence interval and treatment discontinuations.
Start with these studies
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.
Exploratory follow-up after semaglutide or placebo and the accompanying lifestyle intervention were stopped.
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
Randomized withdrawal trial comparing continued tirzepatide with switching to placebo after initial tirzepatide treatment.
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
SUSTAIN 7 was a randomized, open-label phase 3b trial comparing weekly semaglutide with dulaglutide; HbA1c and body weight were assessed at week 40.
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.
A 32-week, double-blind phase 2 trial randomized adults with type 2 diabetes to weekly CagriSema, semaglutide or cagrilintide. The primary outcome was change in HbA1c.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
A randomized, blinded trial compared retatrutide with placebo for weight loss over 48 weeks.
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.
Randomized, double-blind phase 3 trial compared weekly retatrutide with placebo for 40 weeks. The primary outcome was HbA1c, a blood-sugar marker; weight change was secondary.
Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial.
BELIEVE, a randomized phase 2 trial, tested bimagrumab and semaglutide alone or combined for obesity. Common adverse events included gastrointestinal symptoms, muscle spasms and acne.
Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept.
Translational research examined eloralintide, an amylin receptor agonist, for obesity, combining laboratory experiments with an early randomized, blinded, placebo-controlled trial.
Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.
A randomized, double-blind phase 2 substudy in adults with type 2 diabetes compared retatrutide with placebo and dulaglutide. Its primary outcome was total fat-mass change measured by body-composition scans over 36 weeks.
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.
This double-blind, randomized phase 3a trial compared CagriSema with placebo. Primary outcomes were weight change and the proportion losing at least 5%; glucose measures and safety were additional outcomes.
Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.
Phase 3 randomized trial comparing semaglutide with placebo for metabolic fatty liver inflammation and scarring.
Common questions
- What is brenipatide, and how is it different from tirzepatide and retatrutide?
- Could brenipatide reduce alcohol cravings, and what are the trials actually measuring?